Aug 14, 2026 08:00AM
May 12, 2026 08:00AM
Apr 22, 2026 08:02AM
Apr 22, 2026 08:00AM
Mar 6, 2026 08:00AM
Feb 26, 2026 08:01AM
Feb 26, 2026 08:00AM New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
Nov 12, 2025 08:00AM
Oct 24, 2025 11:40AM
Oct 24, 2025 11:39AM
Oct 13, 2025 04:01PM
Oct 13, 2025 04:01PM
Sep 10, 2025 01:45PM
Sep 10, 2025 07:00AM PMV Pharmaceuticals reports cancer drug trial results
Sep 10, 2025 07:00AM
Aug 7, 2025 08:42AM
May 9, 2025 08:00AM
Mar 3, 2025 08:00AM
Nov 7, 2024 08:00AM
Oct 23, 2024 08:00AM
Aug 8, 2024 08:00AM PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial
May 29, 2024 07:04AM
May 29, 2024 07:00AM
May 9, 2024 08:00AM
Mar 27, 2024 08:00AM
Mar 18, 2024 04:01PM
Mar 18, 2024 04:01PM
Feb 29, 2024 04:01PM PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
Jan 18, 2024 04:01PM
Jan 18, 2024 04:01PM
Jan 5, 2024 04:01PM
Jan 5, 2024 04:01PM
Dec 27, 2023 04:16PM
Nov 9, 2023 08:00AM
Oct 12, 2023 12:32PM PMV Pharmaceuticals (PMVP) Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
Oct 12, 2023 12:30PM
Oct 11, 2023 12:00PM
Sep 20, 2023 04:05PM
Aug 9, 2023 08:00AM
May 10, 2023 08:00AM
Mar 1, 2023 08:00AM
Nov 8, 2022 08:00AM PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
Nov 4, 2022 08:02AM
Nov 4, 2022 08:00AM
Aug 9, 2022 08:00AM
Jul 18, 2022 08:07AM
Jul 18, 2022 08:00AM
Jun 7, 2022 12:00PM
Jun 7, 2022 12:00PM PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
Nov 12, 2021 07:15AM

329,915 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All